Biofrontera (BFRI) Liabilities and Shareholders Equity (2020 - 2025)
Biofrontera has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $28.6 million for Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity rose 29.24% year-over-year to $28.6 million; the TTM value through Dec 2025 reached $80.7 million, down 6.98%, while the annual FY2025 figure was $28.6 million, 29.24% up from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 was $28.6 million at Biofrontera, up from $15.4 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $55.1 million in Q3 2022 and troughed at $15.4 million in Q3 2021.
- A 5-year average of $32.3 million and a median of $27.9 million in 2023 define the central range for Liabilities and Shareholders Equity.
- Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 258.6% in 2022 and later tumbled 45.71% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $53.2 million in 2021, then decreased by 4.39% to $50.9 million in 2022, then crashed by 45.11% to $27.9 million in 2023, then dropped by 20.88% to $22.1 million in 2024, then rose by 29.24% to $28.6 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for BFRI at $28.6 million in Q4 2025, $15.4 million in Q3 2025, and $20.1 million in Q2 2025.